Treatment of Psychosis in 2025: Reaching Beyond Dopamine Receptor Blockade

​As clinicians and researchers, we know that current antipsychotic approaches have their limitations for relevant subgroups of patients. Our March session explores innovative agents that target therapeutic pathways, which complement traditional dopamine receptor antagonism.

​Please share your questions when you register.